Jubilant Ingrevia Limited, announced the commissioning of a new facility at its manufacturing site for diketene derivatives at Gajraula, Uttar Pradesh. As a global, integrated life science products and innovative solutions provider, the company presently has over 134 products and innovative solutions commercialised.
Jubilant has developed proficiency across ~35 key chemistry and technology platforms across its businesses: specialty, nutrition and chemical intermediates. The newly commissioned facility adds an additional capacity of ~2,000 TPA to produce high-value esters.
The strengthening of the diketene and derivatives platform marks a natural evolution of strategy in the specialty chemicals segment. The brand is pivoting towards accelerated growth and higher margins with the introduction of several downstream derivatives.
As per the press release, in line with its long-term strategic objectives, Jubilant remains committed to commissioning of future phases of diketene derivatives. In addition to existing clients the expanded range of diketene derivatives will be aimed at a new category of customers in key international markets, including the U.S and E.U regions.
Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited said, “I am happy to emphasise our unwavering dedication to specialty chemicals business with the introduction of this new facility. Diketene and derivatives represent an accelerated growth platform for us. We are committed to cultivating a comprehensive range of advanced product portfolio within this segment with about half a dozen existing derivatives and several new ones in pipeline. Today’s announcement marks an inflection in growth as this advancement will bring us closer to satisfying our client’s needs for innovative products and solutions, leveraging a distinctive and specialised chemistry platform”.
